Skip to main content
Erschienen in: International Journal of Clinical Oncology 4/2017

25.03.2017 | Original Article

The role of LINE-1 methylation in predicting survival among colorectal cancer patients: a meta-analysis

verfasst von: Ding Ye, Danjie Jiang, Yingjun Li, Mingjuan Jin, Kun Chen

Erschienen in: International Journal of Clinical Oncology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

The prognostic value of long interspersed nucleotide element-1 (LINE-1) methylation in patients with colorectal cancer (CRC) remains uncertain. We have therefore performed a meta-analysis to elucidate this issue.

Methods

The PubMed and Web of Science databases were searched for studies published up to 30 June 2016 which reported on an association between LINE-1 methylation and overall survival (OS), disease-free survival (DFS), or cancer-specific survival (CSS) among CRC patients. The reference lists of the identified studies were also analyzed to identify additional eligible studies. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using the fixed-effects or the random-effects model. Stratification analysis and meta-regression analysis were performed to detect the source of heterogeneity. Analyses of sensitivity and publication bias were also carried out.

Results

Thirteen independent studies involving 3620 CRC patients were recruited to the meta-analysis. LINE-1 hypomethylation was found to be significantly associated with shorter OS (HR 2.92, 95% CI 2.20–3.88, p < 0.001) and DFS (HR 2.18, 95% CI 1.46–3.27, p < 0.001), as well as unfavorable CSS (HR 1.96, 95% CI 1.35–2.85, p < 0.001). No heterogeneity was found among the studies evaluating the associations between LINE-1 hypomethylation and OS or DFS, with the exception being CSS. Moreover, meta-regression analysis suggested that one of the contributors to between-study heterogeneity on the association between LINE-1 methylation and CSS was statistical methodology. The subgroup analysis suggested that the association in studies using the Cox model statistical method (HR 2.76, 95% CI 1.90–4.01, p < 0.001) was stronger than that in studies using the Log-rank test (HR 1.41, 95% CI 1.07–1.87, p = 0.015).

Conclusions

The results of this meta-analysis suggest that LINE-1 methylation is significantly associated with the survival of CRC patients and that it could be a predictive factor for CRC prognosis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
15.
Zurück zum Zitat Tang JT, Wang ZH, Fang JY (2015) Assessing the potential value of long interspersed element-1 hypomethylation in colorectal cancer: evidence from retrospective studies. Oncotargets Ther 8:3265–3276. doi:10.2147/Ott.S91941 CrossRef Tang JT, Wang ZH, Fang JY (2015) Assessing the potential value of long interspersed element-1 hypomethylation in colorectal cancer: evidence from retrospective studies. Oncotargets Ther 8:3265–3276. doi:10.​2147/​Ott.​S91941 CrossRef
18.
24.
Zurück zum Zitat DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188CrossRefPubMed DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188CrossRefPubMed
25.
Zurück zum Zitat Greenland S (1987) Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9:1–30CrossRefPubMed Greenland S (1987) Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9:1–30CrossRefPubMed
26.
Zurück zum Zitat Hayashino Y, Noguchi Y, Fukui T (2005) Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol 15(6):235–243CrossRefPubMed Hayashino Y, Noguchi Y, Fukui T (2005) Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol 15(6):235–243CrossRefPubMed
27.
Zurück zum Zitat Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRefPubMed Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRefPubMed
32.
Zurück zum Zitat Kawakami K, Matsunoki A, Kaneko M et al (2011) Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer. Cancer Sci 102(1):166–174. doi:10.1111/j.1349-7006.2010.01776.x CrossRefPubMed Kawakami K, Matsunoki A, Kaneko M et al (2011) Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer. Cancer Sci 102(1):166–174. doi:10.​1111/​j.​1349-7006.​2010.​01776.​x CrossRefPubMed
33.
Zurück zum Zitat Lou YT, Chen CW, Fan YC et al (2015) LINE-1 methylation status correlates significantly to post-therapeutic recurrence in stage III colon cancer patients receiving FOLFOX-4 adjuvant chemotherapy. PLoS One 10(4):1011. doi:10.1371/journal.pone.0123973 CrossRef Lou YT, Chen CW, Fan YC et al (2015) LINE-1 methylation status correlates significantly to post-therapeutic recurrence in stage III colon cancer patients receiving FOLFOX-4 adjuvant chemotherapy. PLoS One 10(4):1011. doi:10.​1371/​journal.​pone.​0123973 CrossRef
34.
36.
Zurück zum Zitat Naito T, Nosho K, Ito M et al (2014) IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions. World J Gastroentero 20(29):10050–10061. doi:10.3748/wjg.v20.i29.10050 CrossRef Naito T, Nosho K, Ito M et al (2014) IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions. World J Gastroentero 20(29):10050–10061. doi:10.​3748/​wjg.​v20.​i29.​10050 CrossRef
40.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. doi:10.1002/ijc.29210 CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. doi:10.​1002/​ijc.​29210 CrossRefPubMed
41.
Zurück zum Zitat Grade M, Becker H, Liersch T et al (2006) Molecular cytogenetics: genomic imbalances in colorectal cancer and their clinical impact. Cell Oncol 28(3):71–84PubMedPubMedCentral Grade M, Becker H, Liersch T et al (2006) Molecular cytogenetics: genomic imbalances in colorectal cancer and their clinical impact. Cell Oncol 28(3):71–84PubMedPubMedCentral
42.
Zurück zum Zitat Levin B, Lieberman DA, McFarland B et al (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134(5):1570–1595. doi:10.1053/j.gastro.2008.02.002 CrossRefPubMed Levin B, Lieberman DA, McFarland B et al (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134(5):1570–1595. doi:10.​1053/​j.​gastro.​2008.​02.​002 CrossRefPubMed
Metadaten
Titel
The role of LINE-1 methylation in predicting survival among colorectal cancer patients: a meta-analysis
verfasst von
Ding Ye
Danjie Jiang
Yingjun Li
Mingjuan Jin
Kun Chen
Publikationsdatum
25.03.2017
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 4/2017
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-017-1106-1

Weitere Artikel der Ausgabe 4/2017

International Journal of Clinical Oncology 4/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.